Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study

BACKGROUND: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. METHODS: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK rearrangements, who had 2 (n = 5), 1 (n = 26) or none (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlov, Sergey V., Iyevleva, Aglaya G., Filippova, Elena A., Lozhkina, Alexandra M., Odintsova, Svetlana V., Sokolova, Tatiana N., Mitiushkina, Natalia V., Tiurin, Vladislav I., Preobrazhenskaya, Elena V., Romanko, Alexandr A., Martianov, Alexandr S., Ivantsov, Alexandr O., Aleksakhina, Svetlana N., Togo, Alexandr V., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144735/
https://www.ncbi.nlm.nih.gov/pubmed/34030112
http://dx.doi.org/10.1016/j.tranon.2021.101121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144735/
https://www.ncbi.nlm.nih.gov/pubmed/34030112
http://dx.doi.org/10.1016/j.tranon.2021.101121

Ejemplares similares